文献速递肿瘤 PET/CT核素与放射性配体治疗

糖-脂-EBV DNA多模态特征预后模型用于局部晚期鼻咽癌个体化风险分层

Multimodal glyco-lipid-EBVDNA signature prognostic model for individualized risk stratification of locally advanced nasopharyngeal carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-02-09

该研究回顾性纳入486例局部晚期鼻咽癌(LA-NPC)患者,在121例代谢组学子队列中整合PET/CT糖酵解参数、血清脂质标志物和预处理EBV DNA,通过递归 partitioning 分析(RPA)构建多模态风险分层模型。模型将患者分为低、中、高危三组,Kaplan–Meier分析显示组间PFS(log-rank P < 0.0001)和OS(log-rank P < 0.001)差异显著,且优于TNM分期和单模态标志物。

要点

  • 基于Lipsig-Score、naso_MTV和EBV DNA的RPA模型可将LA-NPC分为低、中、高危三组。
  • 三组间PFS(P < 0.0001)和OS(P < 0.001)差异显著,模型优于TNM分期和单模态标志物。
  • 该模型整合糖酵解、脂质代谢和病毒因素,为个体化治疗提供风险分层依据。

核心结论

  • 整合糖-脂-病毒轴的多模态模型能捕捉LA-NPC多维生物学特征,实现精准风险分层。
  • 该模型为个体化治疗提供了可靠依据,并优于传统TNM分期和单模态生物标志物。

研究设计与样本

  • 回顾性纳入486例LA-NPC患者,其中121例代谢组学子队列用于模型构建。
  • 通过RPA整合PET/CT糖酵解参数(MTV、TLG)、血清脂质标志物和预处理EBV DNA构建模型。
  • 模型性能与TNM分期及单模态标志物进行比较。

主要发现

  • 在121例LA-NPC患者中通过RPA构建了基于Lipsig-Score、naso_MTV和预处理EBV DNA的多模态模型。
  • 低危组定义为Lipsig-Score < 0.0127且EBV DNA < 500 copies/mL。
  • 中危组定义为Lipsig-Score < 0.0127且EBV DNA ≥ 500 copies/mL,或Lipsig-Score ≥ 0.0127且naso_MTV < 5.5。
  • 高危组定义为Lipsig-Score ≥ 0.0127且naso_MTV ≥ 5.5。
  • Kaplan–Meier分析显示三组间PFS(log-rank P < 0.0001)和OS(log-rank P < 0.001)差异显著,模型优于TNM分期和单模态标志物。

关键数值与推荐

  • 低危:Lipsig-Score < 0.0127 + EBV DNA < 500 copies/mL。
  • 中危:Lipsig-Score < 0.0127 + EBV DNA ≥ 500 copies/mL,或Lipsig-Score ≥ 0.0127 + naso_MTV < 5.5。
  • 高危:Lipsig-Score ≥ 0.0127 + naso_MTV ≥ 5.5。
  • 组间PFS比较log-rank P < 0.0001,OS比较log-rank P < 0.001。

临床怎么用

  • 可利用PET/CT的MTV、血清脂质标志物和EBV DNA对LA-NPC患者进行多模态风险分层。
  • 根据低、中、高危分组辅助个体化治疗决策,弥补TNM分期的不足。

局限性

  • 研究为回顾性设计,代谢组学子队列样本量较小(n = 121)。
  • 模型需在前瞻性队列中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To develop and validate a novel risk stratification model for locally advanced nasopharyngeal carcinoma (LA-NPC) based on the "glyco-lipid-viral" axis, addressing the limitations of traditional TNM staging and single-modality biomarkers. METHODS: A total of 486 LA-NPC patients were retrospectively enrolled, with a metabolomics subcohort (n = 121) selected. PET/CT-derived glycolytic parameters (MTV, TLG), serum lipid biomarkers, and pretreatment EBV DNA were integrated via recursive partitioning analysis (RPA) to construct the model. Its performance was compared with TNM staging and single-modality markers. RESULTS: A multimodal model was built via RPA in 121 LA-NPC patients, using Lipsig-Score (lipid metabolite signature score), naso_MTV (PET/CT), and pretreatment EBV DNA. Three risk groups were defined: low-risk (Lipsig-Score < 0.0127 + EBV DNA < 500 copies/mL), intermediate-risk (Lipsig-Score < 0.0127 + EBV DNA ≥ 500 copies/mL, or Lipsig-Score ≥ 0.0127 + naso_MTV < 5.5), and high-risk (Lipsig-Score ≥ 0.0127 + naso_MTV ≥ 5.5). Kaplan–Meier analysis showed significant differences in PFS (log-rank P < 0.0001) and OS (log-rank P < 0.001) among groups, with the model outperforming TNM staging and single-modal markers. CONCLUSION: The integrated model captures LA-NPC’s multi-dimensional biology, enabling precise risk stratification and providing a reliable basis for individualized treatment.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhou J, Hua Y, Zhang C, et al. Multimodal glyco-lipid-EBVDNA signature prognostic model for individualized risk stratification of locally advanced nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2026. PMID: 41656424. doi:10.1007/s00259-026-07781-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。